Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Protalix Biotherapeutics Inc

PLX ✓ COMPLIANT ☆ Track — members

NYSE American · Healthcare · Pharmaceuticals ·

USA Micro Cap Analyst: BUY

Last Close

$2.22

▼ -5.93%

Market Cap $178.87M · Vol 109.33K

Key Metrics

P/E Ratio

12.16

FWD: 20.94

Market Cap

$178.87M

Micro Cap

Div Yield

N/A

EPS Growth

+343.75%

YoY

RSI (14)

41.67

Momentum

Beta

-0.01

vs Market

52W High

$3.19

30.41% below

52W Low

$1.46

52.58% above

Volume

109.33K

Avg 80.05K

P/B

3.00

Price-to-book

ROE

N/A

Return on equity

Free Float

96.12%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Protalix Biotherapeutics Inc (PLX) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does PLX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-9.76%

-3.90%

+11.00%

-25.25%

YTD

+23.33%

+46.05%

+11.00%

+65.67%

Financials & Valuation

TTM · Annual

Total Revenue	$52.74M
Net Income	$-6,604,000.00
Revenue Growth (YoY)	-99.57%
Gross Margin	48.82%
Operating Margin	-10.43%
Net Profit Margin	-12.52%
ROE	N/A
ROA · ROIC	-7.20% · N/A

P/E Ratio	12.16
Forward P/E (FY1)	20.94
PEG Ratio	N/A
P/S	2.68
P/B	3.00
P/FCF	N/A
EPS Growth	+343.75%
Outstanding Shares	80.57M

Technical Indicators

50-Day SMA	$2.28
200-Day SMA	$2.22
RSI (14)	41.67
Beta	-0.01
52-Week High	$3.19
52-Week Low	$1.46

Volume Today	109.33K
Avg Daily Volume (30D)	80.05K
Relative Volume	1.37x
Volatility (10D)	74.51
Volatility (30D)	50.87
Free Float	96.12%

Analyst Consensus

BUY

Current Price $2.22

Mean Target $11.00

52W Low$1.46 52W High$3.19

Current

Target

$1.46 $3.19

Current Analyst target

+395.50% upside potential · 2 analysts

Identifiers

ExchangeNYSE American

FIGIBBG001SBVMW4

ISINUS74365A3095

CountryUnited States of America

Sub-IndustryPharmaceuticals (NEC)

Earnings DateNov 13, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Co -2.39% JNJ Johnson & Johnson -0.66% ABBV Abbvie Inc -0.54% NVS Novartis AG -0.55% NOVN.S Novartis AG -1.05%

Company Profile

Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.